MKI67 and breast carcinoma: With the positive results, abemaciclib was first approved by the FDA in October 2021 for the adjuvant treatment of early-stage breast cancer in a population limited to those with Ki-67 ≥ 20% in Cohort 1, which comprised 51% of Cohort 1 in the monarchE trial.